PMCB - PharmaCyte Biotech, Inc. Stock Price, Fair Value and News

2.12USD0.00 (0.00%)Delayed as of 30 Apr 2024, 11:31 am ET

Market Summary

USD2.120.00

Delayedas of 30 Apr 2024, 11:31 am

0.00%

PMCB Stock Price

View Fullscreen

PMCB RSI Chart

PMCB Valuation

Market Cap

17.9M

Price/Earnings (Trailing)

-15.75

Price/Sales (Trailing)

5.61

Price/Free Cashflow

-8.52

PMCB Price/Sales (Trailing)

PMCB Profitability

Operating Margin

100.00%

Return on Equity

-3.63%

Return on Assets

-1.6%

Free Cashflow Yield

-11.74%

PMCB Fundamentals

PMCB Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

38.65%

Rev. Growth (Qtr)

69.85%

PMCB Earnings

Earnings (TTM)

-1.1M

Earnings Growth (Yr)

18.92%

Earnings Growth (Qtr)

-122.21%

Breaking Down PMCB Revenue

52 Week Range

2.023.23

(Low)(High)

Last 7 days

-4.5%

Last 30 days

-10.5%

Last 90 days

-5.8%

Trailing 12 Months

-27.4%

How does PMCB drawdown profile look like?

PMCB Financial Health

Current Ratio

8.16

PMCB Investor Care

Buy Backs (1Y)

57.78%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.2M	0	0	0
2023	3.2M	4.5M	3.9M	3.0M
2022	861.7K	809.5K	1.5M	2.7M
2021	442.9K	586.2K	630.2K	826.7K
2020	399.8K	459.1K	490.7K	463.7K
2019	425.0K	300.0K	262.5K	340.5K
2018	534.7K	617.4K	569.9K	474.9K
2017	481.7K	478.7K	495.8K	571.4K
2016	389.1K	458.4K	511.3K	510.1K
2015	2.1M	884.3K	748.6K	453.3K
2014	1.3M	1.5M	1.7M	1.9M
2013	510.8K	706.1K	901.5K	1.1M
2012	268.7K	341.6K	333.8K	425.6K
2011	0	50.0K	122.9K	195.8K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold PMCB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	EQUITEC PROPRIETARY MARKETS, LLC	added	100	213,436	392,126	0.11%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-35,852	-	-%
Apr 23, 2024	BFSG, LLC	new	-	17.00	17.00	-%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	1.00	5.00	-%
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	168	1,896	-%
Apr 05, 2024	Carolina Wealth Advisors, LLC	unchanged	-	-	4.00	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	2,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.43	15,350	370,084	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-46.55	-108	135	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-19.12	-12,491	61,815	-%

Are Funds Buying or Selling PMCB?

Are funds buying PMCB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMCB

No. of Funds

Unveiling PharmaCyte Biotech, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ayrton capital llc	9.9%	956,229	SC 13G
Feb 06, 2024	intracoastal capital, llc	9.99%	903,412	SC 13G/A
Jun 16, 2023	iroquois capital management, llc	4.99%	178,654	SC 13D/A
May 19, 2023	ayrton capital llc	9.99%	1,750,712	SC 13G
May 12, 2023	iroquois capital management, llc	6.6%	1,174,245	SC 13D/A
Feb 14, 2023	shay capital llc	0.00%	0	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	8.4%	1,606,042	SC 13G/A
Jan 10, 2023	sabby management, llc	4.99%	934,456	SC 13G/A
Oct 20, 2022	shay capital llc	5.00%	1,037,882	SC 13G
Aug 15, 2022	iroquois capital management, llc	6.4%	1,321,499	SC 13D/A

Recent SEC filings of PharmaCyte Biotech, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 27, 2024	DEF 14A	DEF 14A
Mar 27, 2024	ARS	ARS
Mar 18, 2024	10-Q	Quarterly Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 06, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to PharmaCyte Biotech, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

PharmaCyte Biotech, Inc. News

Latest updates

PharmaCyte Biotech, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	69.9%	882	519	325	1,473	636	1,455	896	208	131	285	186	260	96.00	88.00	142	117	117	115	110	58.00	57.00
Operating Expenses	32.6%	1,869	1,410	2,075	903	1,553	2,319	1,681	1,508	856	1,005	1,023	1,035	757	950	882	750	875	1,067	1,134	1,172	676
S&GA Expenses	-7.6%	252	273	1,355	328	357	183	245	254	215	259	362	127	85.00	88.00	118	175	160	405	423	523	138
R&D Expenses	54.5%	127	82.00	104	86.00	45.00	178	159	254	158	135	144	320	174	151	271	98.00	113	18.00	72.00	18.00	59.00
Interest Expenses	-	-	-	-	-	-	-	-	-	-	42*	467*	1.00	249*	677*	388*	453*	-	-	-	-	-
Income Taxes	-	-	-	2.00	-	-	-	-	-	-	-	2.00	-	-	-	800*	-	-	-	800*	800*	-
Net Income	-122.2%	-619	2,790	-3,183	-126	-764	-1,880	-1,545	-1,422	-811	-979	-1,025	-960	-757	-950	-883	-750	-875	-1,067	-1,134	-1,138	-676
Net Income Margin	18.1%	-0.36*	-0.43*	-2.81*	-1.61*	-2.11*	-2.10*	-3.13*	-5.24*	-4.38*	-4.50*	-5.86*	-6.06*	-7.54*	-7.46*	-	-	-	-	-	-	-
Free Cashflow	91.1%	-177	-1,984	343	-288	-541	-1,879	-1,084	-1,191	-298	-1,385	-1,241	-940	-589	-1,250	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.5%	71,359	78,878	79,880	73,277	77,951	82,349	87,385	90,624	91,943	92,310	6,637	7,404	8,262	8,941	7,432	6,167	5,338	5,338	5,606	5,782	5,837
Current Assets	-16.6%	61,508	73,748	74,751	68,148	72,821	77,219	82,256	85,495	86,814	87,180	1,508	2,275	3,133	3,812	2,303	1,038	209	209	477	653	708
Cash Equivalents	-16.6%	61,210	73,425	74,663	68,040	72,640	76,963	82,228	85,401	86,640	86,939	959	2,202	3,091	3,717	2,167	895	142	45.00	328	515	699
Liabilities	7.9%	22,466	20,813	20,397	10,612	828	1,311	1,089	704	613	186	925	725	649	665	1,187	1,078	1,019	804	607	743	471
Current Liabilities	43.9%	7,539	5,240	1,518	587	828	1,311	1,089	704	613	186	925	725	640	644	1,153	1,031	1,019	804	607	743	471
Shareholder's Equity	-14.7%	31,375	36,768	39,194	72,690	77,123	81,038	86,296	89,920	91,330	92,124	5,712	6,679	7,613	8,277	6,245	5,089	4,319	4,534	4,999	5,040	5,366
Retained Earnings	-0.5%	-116,971	-116,352	-119,461	-115,958	-115,838	-115,074	-113,193	-111,648	-110,225	-109,414	-108,434	-107,409	-106,449	-105,692	-104,742	-103,858	-103,107	-102,232	-101,165	-100,031	-98,892
Additional Paid-In Capital	-2.3%	189,221	193,591	202,231	202,231	202,231	201,601	201,593	201,582	201,573	201,555	114,169	114,109	113,849	113,757	110,819	108,969	107,306	106,655	106,060	104,966	104,154
Shares Outstanding	-2.1%	8,521	8,700	8,778	16,794	20,052	20,585	20,829	20,721	13,539	17,358	1,591	1,590	1,406	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	54,212	-	-	-	58,283	-	-	-	20,215	-	-	-	44,428	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	91.1%	-177	-1,984	343	-288	-541	-1,879	-1,084	-1,191	-298	-1,385	-1,241	-940	-589	-1,250	-551	-639	-352	-583	-763	-661	-676
Share Based Compensation	-	675	-	-	-314	629	4.00	3.00	4.00	7.00	10.00	11.00	11.00	49.00	67.00	67.00	59.00	100	105	105	48.00	61.00
Cashflow From Investing	-Infinity%	-5,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-1040.2%	-7,038	749	6,279	-4,306	-3,778	-3,385	-2,089	-50.80	-	87,362	-	51.00	-38.17	2,804	1,820	1,392	450	301	583	483	465
Buy Backs	142.9%	405	167	26,722	4,307	3,778	3,385	2,091	-	-	-	-	-	-	-	-	-	450	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PMCB Income Statement

2024-01-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development costs	126,732	45,393	313,248	382,662
Compensation expense	620,777	251,556	1,089,934	979,694
Director fees	638,762	795,969	995,715	951,031
Legal and professional	230,772	103,180	1,075,073	2,454,227
General and administrative	251,903	356,885	1,879,822	784,597
Total operating expenses	1,868,946	1,552,983	5,353,792	5,552,211
Loss from operations	(1,868,946)	(1,552,983)	(5,353,792)	(5,552,211)
Other income (expenses):
Interest income	881,662	635,889	2,651,721	1,214,562
Change in fair value of warrant liability	10,000	0	2,633,000	0
Change in fair value of derivative liability	636,000	0	(663,000)	0
Change in fair value of convertible note receivable	138,000	0	138,000	0
Change in fair value of warrant asset	(416,000)	0	(416,000)	0
Other income (expense), net	(253)	152,958	(2,867)	147,994
Total other income, net	1,249,409	788,847	4,340,854	1,362,556
Net loss	(619,537)	(764,136)	(1,012,938)	(4,189,655)
Preferred stock dividends	(781,507)	0	(1,688,242)	0
Preferred stock accretion	(4,219,069)	0	(11,995,681)	0
Net loss attributable to common stockholders	$ (5,620,113)	$ (764,136)	$ (14,696,861)	$ (4,189,655)

PMCB Balance Sheet

2024-01-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Current assets:
Cash and cash equivalents	$ 61,210,328	$ 68,039,936
Prepaid expenses and other current assets	297,762	107,681
Total current assets	61,508,090	68,147,617
Other assets:
Intangibles	3,549,427	3,549,427
Investment in SG Austria	1,572,193	1,572,193
Convertible note receivable	2,012,000	0
Warrant asset	2,710,000	0
Other assets	7,688	7,688
Total other assets	9,851,308	5,129,308
Total Assets	71,359,398	73,276,925
Current liabilities:
Accounts payable	484,198	128,281
Accrued expenses	774,439	458,300
Accrued Series B convertible preferred stock redemptions and dividends	6,280,102	0
Total current liabilities	7,538,739	586,581
Other liabilities:
Warrant liability	11,494,000	0
Derivative liability	3,433,000	0
Total other liabilities	14,927,000	0
Total Liabilities	22,465,739	586,581
Commitments and Contingencies (Notes 7 and 9)
Stockholders' equity:
Preferred stock value	0	0
Common stock, authorized: 200,000,000 shares, $0.0001 par value; 21,672,078 shares issued and 8,521,159 shares outstanding as of January 31, 2024 and 21,602,078 shares issued and 16,793,980 shares outstanding as of April 30, 2023	2,167	2,160
Additional paid-in capital	189,221,416	202,230,583
Accumulated deficit	(116,971,711)	(115,958,773)
Treasury stock, at cost, 13,150,919 and 4,808,098 shares as of January 31, 2024 and April 30, 2023, respectively	(40,853,840)	(13,560,623)
Accumulated other comprehensive loss	(23,073)	(23,003)
Total stockholders' equity	31,374,959	72,690,344
Total Liabilities, Convertible Preferred Stock and Stockholders' Equity	71,359,398	73,276,925
Series B Preferred Stock [Member]
Convertible Preferred Stock:
Convertible preferred stock	17,518,700	0
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock value	$ 0	$ 0

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

CEO	Mr. Joshua N. Silverman
WEBSITE	https://pharmacyte.com
INDUSTRY	Biotechnology
EMPLOYEES	2

PharmaCyte Biotech, Inc. Frequently Asked Questions

What is the ticker symbol for PharmaCyte Biotech, Inc.? What does PMCB stand for in stocks?

PMCB is the stock ticker symbol of PharmaCyte Biotech, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PharmaCyte Biotech, Inc. (PMCB)?

As of Mon Apr 29 2024, market cap of PharmaCyte Biotech, Inc. is 17.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMCB stock?

You can check PMCB's fair value in chart for subscribers.

What is the fair value of PMCB stock?

You can check PMCB's fair value in chart for subscribers. The fair value of PharmaCyte Biotech, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PharmaCyte Biotech, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMCB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PharmaCyte Biotech, Inc. a good stock to buy?

The fair value guage provides a quick view whether PMCB is over valued or under valued. Whether PharmaCyte Biotech, Inc. is cheap or expensive depends on the assumptions which impact PharmaCyte Biotech, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMCB.

What is PharmaCyte Biotech, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, PMCB's PE ratio (Price to Earnings) is -15.75 and Price to Sales (PS) ratio is 5.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PMCB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on PharmaCyte Biotech, Inc.'s stock?

In the past 10 years, PharmaCyte Biotech, Inc. has provided 0.334 (multiply by 100 for percentage) rate of return.